Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $3.8 million.

  • Enanta Pharmaceuticals' Share-based Compensation fell 3275.68% to $3.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $16.7 million, marking a year-over-year decrease of 3141.37%. This contributed to the annual value of $18.6 million for FY2025, which is 3071.47% down from last year.
  • As of Q4 2025, Enanta Pharmaceuticals' Share-based Compensation stood at $3.8 million, which was down 3275.68% from $4.0 million recorded in Q3 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Share-based Compensation registered a high of $8.1 million during Q4 2023, and its lowest value of $3.8 million during Q4 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' median Share-based Compensation value was $5.9 million (recorded in 2021), while the average stood at $6.0 million.
  • In the last 5 years, Enanta Pharmaceuticals' Share-based Compensation surged by 3886.76% in 2022 and then crashed by 4773.26% in 2025.
  • Enanta Pharmaceuticals' Share-based Compensation (Quarter) stood at $6.1 million in 2021, then increased by 17.77% to $7.1 million in 2022, then grew by 13.45% to $8.1 million in 2023, then plummeted by 30.04% to $5.7 million in 2024, then plummeted by 32.76% to $3.8 million in 2025.
  • Its last three reported values are $3.8 million in Q4 2025, $4.0 million for Q3 2025, and $4.2 million during Q2 2025.